Sorrento Therapeutics Inc (SRNE)

[dia76ca]

In a late March interview Dr.Ji emphasized SEMDEXA aiming for Breakthrough Designation followed by marketing approval within 6 months...target late 2022 or early 2023. Also Mpro oral antiviral enter clinic in April with signs it does not have drug/drug interactions of the Pfizer drug. COVISHIELD covers all covid variants and might be ready in Q4 2022. COVIMARK approval packages before US FDA and Health Canada. AND application for COVIMARK APPROVAL IN CHINA...gigantic market!
Here are 10 potential news items in 2022 and/34 top programs out of the 70+ total pipeline.
1. ABIVERTINIB $61 Billion global market partnership(s). There would be multi-billion upfront, milestone and royalty payments. They announced partnering intentions in June last year! Remember the Genentech/Roche scenario!
2. SCILEX SPINOFF. More SEMDEXA news is due any day. This new treatment could gross $6-10 billion annually in the US alone!.
3. COVISTIX(COVIMARK) REVENUE STREAM. Sales have recorded in Q1 of 2022. Mexico leads the way and Europe, Central and South America, Canada, Japan and the US will follow. 30 million monthly test production near term! And now seeking approval in huge China market!
4. COVIDROPS, COVI-MSC, COVISHIELD, SEMDEXA, ABIVERTINIB(cancer and Covid) news is expected in 2022 and more EUA's. SEMDEXA and ABIVERTINIB potential revenue in 2H of 2022?
5. COVIDROPS is in phase 2 in the US and UK. Soon to enter a pediatric trial in Mexico. An Interim analysis of the UK out-patient trial any day.
6. COVI-MSC is in phase 2 trials in the US and Brazil The Brazilian study is pivotal. In Brazil it is followed by a trial for long-haul Covid patients.
7. ORAL MP18 based PAN-COVID ANTI-VIRAL. A peer-reviewed publication was released showing strong pan-Covid activity (including Omicron). A prestigious European journal made it front page news. This could enter the clinic in Q2(April).
8. In Cancer Sorrento has more than 10 fully human antibodies in the clinic or late pre-clinical(PD-1, PD-L1, CD38, CD123, CD47,BCMA, TROP2, LAG3, CTLA-4 and CD137). An allogenic DAR-T, an anti-TROP2 ADC and a second generation oncolytic virus(Seprehvec) will enter the clinic with several ADNAB(Mayo Clinic) drugs.
9. Non-opioid RTX is in phase 2 for arthritic knee pain and will enter phase 2 for epidural delivery for severe cancer pain in Q1.
10. Sofusa will report on a phase 1 arthritis treatment in Q2. Also is being tested in delivering cancer therapies including a collaboration with the Mayo Clinic to test lymphatic delivery.
And have a look at the top 34 portfolio items from the SRNE website. No wonder Blackrock holds over 22 million shares!
https://sorrentotherapeutics.com/research/pipeline/

FUNDING? Sorrento has invested wisely and has millions of shares of Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments!